CCO Oncology Podcast artwork

The Evolving Role of TKIs in First-line Treatment of Advanced HCC

CCO Oncology Podcast

English - December 14, 2021 16:30 - 13 minutes - 12.2 MB
Courses Education Health & Fitness Medicine essential thrombocythemia myelofibrosis oncology cme skin cancer acute myeloid leukemia kidney cancer melanoma gastrointestinal cancer prostate can Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Expert Insight on Important Clinical Trial Data From ESGO 2021 Informing Treatment for Ovarian Cancer and Endometrial Cancers
Next Episode: Key Factors Influencing Later-Line Treatment Selection for Patients With Metastatic Colorectal Cancer

In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss first-line treatment of patients with advanced hepatocellular carcinoma. Topics include:

Atezolizumab plus bevacizumab as the current standard of careContraindications to atezolizumab plus bevacizumabThe current role of tyrosine kinase inhibitors in first-line treatment of advanced hepatocellular carcinomaOngoing clinical trials in the first-line setting

Presenters:  

Josep M. Llovet, MD, PhD, FAASLD
Professor of Medicine
Director, Mount Sinai Liver Cancer Program
Division of Liver Diseases
Mount Sinai School of Medicine
New York, NY
Professor of Research
Liver Unit, IDIBAPS
Hospital Clinic Barcelona
Barcelona, Spain

Univ. Prof. Markus Peck-Radosavljevic, MD, MBA
Professor of Medicine, Medical University of Vienna
Vienna, Austria
Department Chair, Innere Medizin and Gastroenterologie
Klinikum Klagenfurt am Wörthersee
Klagenfurt am Wörthersee, Austria

Link to full program, including accompanying downloadable slidesets:
https://bit.ly/2ZL9bxq